Answers are grounded in this paper and cite their sources.
Compares treatment tolerability in older adults with cancer using geriatric assessment versus oncologist guidance, indicating improved outcomes.
PURPOSE Primary treatment modification (PTM; changes in treatment dose or agents from standard guidelines) is common among older adults with advanced cancer because of aging-related vulnerabilities. Geriatric assessment evaluates aging-related factors to inform personalized treatment. We compared treatment tolerability between PTM guided by geriatric assessment–guided management (PTM-GAM) and PTM determined by usual oncologic care (PTM-UC). METHODS This secondary analysis of the GAP70+ study (ClinicalTrials.gov identifier: NCT02054741 ; PI: Mohile) was restricted to patients age 70+ years with incurable solid tumors who initiated systemic therapy with a PTM (N=298). PTM-GAM (n = 169) was guided by GA results and management recommendations, whereas PTM-UC (n = 129) was based solely on oncologist evaluation. Tolerability outcomes within 3 months of treatment initiation included grade 3 to 5 toxicity, secondary dose reduction (any unplanned decrease in dose after treatment initiation), decline in activities of daily living (ADL), and unplanned hospitalization. Associations were evaluated using multivariable cluster-weighted generalized estimating equation models. RESULTS The mean age was 77 years, and GI cancers were most common (37%). Overall, 59% experienced ≥1 grade 3 to 5 toxicity. Compared with PTM-UC, PTM-GAM was associated with a lower risk of grade 3 to 5 toxicity (relative risk, 0.77 [95% CI, 0.65 to 0.91]). Secondary dose reductions occurred in 22% of patients, with lower risk in PTM-GAM (RR, 0.47 [95% CI, 0.30 to 0.72]). PTM-GAM was associated with a nonsignificant reduction in unplanned hospitalization (RR, 0.69 [95% CI, 0.45 to 1.03]). No difference was observed in ADL decline (RR, 1.04 [95% CI, 0.74 to 1.48]). CONCLUSION Older adults with advanced cancer who received GA-guided PTM had a 23% lower risk of grade 3 to 5 toxicities and a 53% lower risk of secondary dose reduction compared with PTM based on usual oncologic care. These findings underscore the role of geriatric assessment in optimizing treatment decisions and improving tolerability.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: